Oct
2026
Fiera Milano, Italy
Visit us
stand 16F1, Finished Dosage & Formulation

Dexa Medica PT

Exhibitor at CPHI Milan 2026
About Us

Dexa Medica, one of Indonesia’s largest pharmaceutical companies, has consistently used its sophisticated research capabilities to prioritize Indonesia’s public health needs. Its motto — to use expertise for the promotion of health — is a natural consequence of this long-standing commitment to improving healthcare for all. 

Read more Show less
Sales Markets
Show more Show less
Categories
more categories Show less
  • Country/Region:
    Indonesia
  • On CPHI since:
    2020
  • Certificates:
    3
  • Employees:
    5000+
Company types
CMO/CDMO
Manufacturer/Innovator
Pharmaceutical company
Primary activities
Contract Manufacturer
Pharmaceutical Company (generic finished products)
Pharmaceutical Company (innovator finished products)
View company profile
Contact info
Show contact info Hide contact info
Event information
CPHI Milan 2026
  • 6 Oct 2026 - 8 Oct 2026
  • Fiera Milano, Italy
  • Visit us at stand 16F1, Finished Dosage & Formulation

Products Featured at CPHI Milan 2026

  • Dexa Group - Evidenced based natural medicines

    Product Dexa Group - Evidenced based natural medicines

    https://www.dexagroup.com/advanced-herbal-medicines/
  • Dexa Group - Full Product List

    Product Dexa Group - Full Product List

    https://www.dexagroup.com/products/ This includes are generics, natural medicines and VMS
  • Bendamustine 25, 100

    Product Bendamustine 25, 100

    PT. Fonko international Pharmaceuticals offers a wide range of oncology finished dosage which includes Bendamustine 25 mg and 100 mg. Indication : Chronic lymphocytic Leukemia, Non-Hodgin Lymphoma and Multiple Myeloma. Contact us for more information
  • Bortezomib 1, 3.5

    Product Bortezomib 1, 3.5

    PT. Fonko international Pharmaceuticals offers a wide range of oncology finished dosage which includes Bortezomib 1 mg, 3.5 mg Indication : multiple myeloma, mantle cell lymphoma. Contact us for more information
  • Carboplatin 150, 450

    Product Carboplatin 150, 450

    PT. Fonko international Pharmaceuticals offers a wide range of oncology finished dosage which includes Carboplatin 150 mg, 450 mg. Indication : Initial treatment of advance ovarian carcinoma, Secondary treatment of advance ovarian carcinoma. Contact us for more information

Dexa Medica Resources (1)